RxDoctor Payments Data

James Bresee, MD

Urology · Portland, ORNPI 1730484544

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $12,153 of the $14,300 with a category attached, or 85.0%. It is spread thinly across 60 manufacturers, the largest accounting for just 18.3% — the pattern of someone who eats at a lot of different presentations. Among urology clinicians in OR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$14,300in general payments, 2019–2025

Across 557 payments — averaging $25.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$3K
  • Astellas Pharma US Inc$1K
  • AbbVie$1K
  • Sumitomo Pharma America, Inc.$1K
  • Dendreon Pharmaceuticals LLC$906
  • Johnson & Johnson$702
  • plus $6K from 54 others

What the payments were for

  • Speaking & faculty fees$1,87513%
  • Food & beverage$12,15385%
  • Education$2722%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Boston Scientific36$2,613
Astellas Pharma US Inc57$1,320
AbbVie(2 entities)71$1,285
Sumitomo Pharma America, Inc.27$1,022
Dendreon Pharmaceuticals LLC40$906
Johnson & Johnson(2 entities)34$702
Pfizer32$543
Bayer21$479
Accord Healthcare, Inc.21$413
Tolmar, Inc.13$369
Ferring Pharmaceuticals Inc.20$348
Merck11$271
Amgen11$270
AstraZeneca8$218
Endo Pharmaceuticals Inc.14$217
Coloplast11$180
Urogen Pharma, Inc.7$168
Myriad Genetic Laboratories, Inc.9$166
Verity Pharmaceuticals Inc.5$150
Telix Pharmaceuticals4$142
Antares Pharma, Inc.7$135
Blue Earth Diagnostics5$125
Smith+Nephew5$124
Novartis5$119
Myovant Sciences Inc.6$118
Teleflex LLC3$112
Travere Therapeutics, Inc.5$110
EDAP Technomed Inc1$109
Progenics Pharmaceuticals, Inc.4$100
Olympus America Inc.5$96
C. R. Bard, Inc. & Subsidiaries2$95
Convatec Inc.4$89
Endo USA, Inc.4$86
Laborie Medical Technologies Corp.3$85
Vertex3$81
Axonics, Inc.2$81
Janssen Scientific Affairs, LLC4$76
Sun Pharmaceutical Industries Inc.2$67
180 Medical, Inc.2$59
Valencia Technologies Corporation3$57
Tolmar Pharmaceuticals, Inc.3$54
Halozyme Inc2$50
Neotract Inc.3$46
Immunitybio, Inc.2$45
Zyla Life Sciences, Inc.3$44
BD1$39
Urovant Sciences Inc2$38
Agiliti Surgical, Inc.1$28
Dornier Medtech America, Inc1$28
KARL Storz Endoscopy-america1$25
Palette Life Sciences, Inc.1$23
Profound Medical Corp.1$22
Foundation Medicine, Inc.1$22
Therapeuticsmd, Inc.1$21
Sanofi1$18
Baxter Healthcare1$17
Mallinckrodt Enterprises LLC1$17
Cook Medical LLC1$16
Innovation Technologies Inc1$16
Medline Industries LP1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,300 in reported general payments places this provider in the 90th percentile of 153 urology providers in Oregon.

See all urology providers in Oregon

Medicare billing

Part B allowed, 2024
$473,867
Medicare patients
458
Services billed
8,251

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron135$152,817
MyrbetriqMirabegron55$62,150
Tamsulosin Hcl755$10,879
Finasteride810$9,829
Testosterone19$3,513
NitrofurantoinNitrofurantoin Macrocrystal38$2,169
Trospium Chloride18$1,479
Tadalafil29$866
Testosterone Cypionate11$796
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen141$701
Oxybutynin Chloride89$572
Cephalexin12$276
Sildenafil Citrate15$197
Levofloxacin87$184
Meloxicam22$180

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$1,022$152,817135 claims
Astellas Pharma US IncMyrbetriq$1,320$62,15055 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 153 urology providers in Oregon.

Other urology in Portland

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →